Alpha 2.0
Login Register
» Authors » Bertrand J Jean-Claude

Bertrand J Jean-Claude

Explore the profile of Bertrand J Jean-Claude including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 56
Citations 310
Followers 0
Related Specialties
Oncology
Pharmacology
Chemistry
Top 10 Co-Authors
Zakaria Rachid
Qiyu Qiu
Fouad Brahimi
Christopher Williams
James P McNamee
Ranjita Banerjee
Ying Huang
Anne-Laure Larroque-Lombard
Anne-Laure Larroque
Athanasia Katsoulas
Published In
J Med Chem
Anticancer Drugs
Chem Biol Drug Des
Invest New Drugs
J Pharmacol Exp Ther
Affiliations
Soon will be listed here.
Recent Articles
21.
Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach
Al-Safadi S, Domarkas J, Han Y, Brahimi F, Jean-Claude B
Anticancer Drugs . 2012 Mar; 23(5):483-93. PMID: 22421369
ZRBA1 is a quinazoline-based molecule termed 'combi-molecule' designed to block the epidermal growth factor receptor (EGFR) and further degrade to FD105, an EGFR inhibitor plus a DNA-alkylating agent. To augment...
22.
"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer
Fang Y, Qiu Q, Domarkas J, Larroque-Lombard A, Rao S, Rachid Z, et al.
Prostate . 2012 Feb; 72(12):1273-85. PMID: 22290742
Purpose: At the preclinical stage, mitozolomide (MTZ) showed exciting preclinical activity but failed later in clinical trial due to toxic side effects. We surmised that by targeting MTZ to epidermal...
23.
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda
Ait-Tihyaty M, Rachid Z, Mihalcioiu C, Jean-Claude B
Breast Cancer Res Treat . 2011 Sep; 133(1):217-26. PMID: 21915635
Capecitabine (Xeloda) is a prodrug of 5-FU used in the clinical management of advanced breast cancer. It is metabolized first in the liver by carboxylesterases to generate 5'-deoxy-5-flurocytidine ribose (5'-DFCR),...
24.
A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity
Golabi N, Brahimi F, Huang Y, Rachid Z, Qiu Q, Larroque-Lombard A, et al.
J Pharm Biomed Anal . 2011 Jul; 56(3):592-9. PMID: 21764236
ZR2003 is a type II of combi-molecule designed to target DNA and the epidermal growth factor receptor (EGFR) without requirement for hydrolysis. In human tumour cell lines cultured as monolayers,...
25.
Synthesis, characterization and anticancer studies of mixed ligand dithiocarbamate palladium(II) complexes
Khan H, Badshah A, Murtaz G, Said M, Rehman Z, Neuhausen C, et al.
Eur J Med Chem . 2011 Jul; 46(9):4071-7. PMID: 21724304
Six mixed ligand dithiocarbamate Pd(II) complexes (1-6) of general formula [(DT)Pd(PR(3))Cl], where DT = dimethyldithiocarbamate (1, 5), diethyldithiocarbamate (2, 3), dicyclohexyldithiocarbamate (4), bis(2-methoxyethyl)dithiocarbamate (6); PR(3) = benzyldiphenylphosphine (1), diphenyl-2-methoxyphenylphosphine (2),...
26.
In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-molecule
Golabi N, Rachid Z, Qiu Q, Huang Y, Jean-Claude B
Drug Metab Lett . 2011 Apr; 5(2):141-9. PMID: 21457144
Combi-molecules are agents designed to block receptors on their own and to further degrade to bioactive agents. Here we studied the fate of a novel combi-molecule of triazene class termed...
27.
MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1
Huang Y, Rachid Z, Jean-Claude B
Mol Cancer Res . 2011 Jan; 9(3):320-31. PMID: 21263032
To enhance the potency of current EGFR inhibitors, we developed a novel strategy that seeks to confer them an additional DNA damaging function, leading to the design of drugs termed...
28.
The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle
Banerjee R, Huang Y, Qiu Q, McNamee J, Belinsky G, Jean-Claude B
Cell Signal . 2010 Dec; 23(4):630-40. PMID: 21138763
RB24 (NSC 741279), a 3-methyltriazene termed "combi-molecule" designed to possess mixed epidermal growth factor receptor (EGFR) targeting and DNA methylating properties showed over a 100-fold greater antiproliferative activity than Temodal(®)...
29.
Antineoplastic Activity of New Transition Metal Complexes of 6-Methylpyridine-2-carbaldehyde-N(4)-ethylthiosemicarbazone: X-Ray Crystal Structures of [VO(2)(mpETSC)] and [Pt(mpETSC)Cl]
Elsayed S, El-Hendawy A, Mostafa S, Jean-Claude B, Todorova M, Butler I
Bioinorg Chem Appl . 2010 Jul; :149149. PMID: 20671978
New complexes of dioxovanadium(V), zinc(II), ruthenium(II), palladium(II), and platinum(II) with 6-methylpyridine-2-carbaldehyde-N(4)-ethylthiosemicarbazone (HmpETSC) have been synthesized. The composition of these complexes is discussed on the basis of elemental analyses, IR, Raman,...
30.
Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain
MacPhee M, Rachid Z, Todorova M, Qiu Q, Belinsky G, Jean-Claude B
Invest New Drugs . 2010 Apr; 29(5):833-45. PMID: 20428924
Previous strategies for stabilizing combi-triazenes were based on masking the 1,2,3-triazene chain with a 3-acetoxymethylene group. The half-lives of the latter molecules were only ca 5 min longer than those...